RedHill Biopharma’s $39 Million Underwritten Public Offering

Gornitzky represented the underwriters, led by Roth Capital Partners, in RedHill Biopharma’s USD 39 million underwritten public offering of American Depositary Shares (ADSs) and warrants on the NASDAQ Capital Market and concurrent registered direct offering of its ADSs and warrants.

RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on drugs for inflammatory and gastrointestinal diseases and cancer, is dually traded on the NASDAQ and the Tel Aviv Stock Exchange (NASDAQ: RDHL, TASE: RDHL).

Roth Capital Partners acted as the sole book-running manager and Echelon Wealth Partners acted as Canadian manager for the underwritten public offering with respect to sales in Canada. Roth Capital Partners acted as placement agent in the registered direct offering.

The underwriters were represented by Chaim Friedland (Picture) and Ari Fried (Partner).

Involved fees earner: Chaim Friedland – Gornitzky & Co.; Ari Fried – Gornitzky & Co.;

Law Firms: Gornitzky & Co.;

Clients: Roth Capital Partners, LLC;


Author: Michael Patrini.